% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

  • sudhanva_n sudhanva_n Feb 16, 2013 8:52 AM Flag

    Tubulysin - Crown Jewel

    Tubulysin A (tubA) is a natural product isolated from a strain of myxobacteria that has been shown to depolymerize microtubules and induce mitotic arrest. The potential of tubA as an anticancer and antiangiogenic agent is explored in the present study. tubA shows potent antiproliferative activity in a panel of human cancer cell lines irrespective of their multidrug resistance properties. It induces apoptosis in cancer cells but not in normal cells and shows significant potential antiangiogenic properties in several in vitro assays. It is efficacious in initial animal studies using a hollow fibre assay with 12 different human tumour cell lines. This study suggests that both in vitro and preclinical profiles of tubA may translate into clinically useful anticancer properties.
    In one of the conference the CEO said that Tubulysin was not on the table during negotiation with MRK.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hi Sudhanva, I have been thinking about buying some ECYT, I heard a potential EOY price at $18.00. Is there something coming out in May or June with this company?? ECYT’s has two preclinical-stage drug candidates, EC0531 and EC1069, and we expect INDs to be filed for EC0531 in 1H13 and for EC1069 by the end of 2013. ECYT’s folate/tubulysin B SMDC (EC0531) is a highly promising drug candidate with its high potency, a potential for multi-drug resistance, and good tolerability in preclinical models. ECYT recently completed an early clinical imaging study for EC0652 and a potential diagnostic test for EC1069, a SMDC-targeting PSMA.

      • 1 Reply to da_dev
      • da_dev,

        The first major catalyst is provisional EMA approval for PROC in Europe. This might happen before end of the year. The next major catalysts for ECYT would be in first half of next year namely, PROC phase 3 results and NSCLC phase 2 results.. The other catalysts would be MRK starting 4 trials for different indications. They have almost 190 plus million dollars in cash with a EV of 140 million. Most of the cost is shared by MRK and ECYT has a burn rate 40-45 million per year. If the previous results holds good PROC and NSCLC trials should be successful. MRK would not want to pay 880 million in royalties and 50 % cut in US sales, they will just buy them. Arguably the most undervalued biotech stock with a billion dollar deal with the a big pharma.

        Sentiment: Strong Buy

    • sudhanva_n

      thanks for your post,

      can you be more specific about the conference you have cited?
      when was that conference held? any replay webcast available?

5.09-0.07(-1.36%)3:28 PMEDT